The Health and Information and Quality Authority (Hiqa) has released a health technology assessment, shedding light on the potential of expanding respiratory syncytial virus (RSV) vaccination to infants in Ireland. This assessment highlights the significant impact such a strategy could have on reducing hospitalisations and improving public health. Here's a breakdown of the key findings and the broader implications.
Expanding Vaccination to Infants
Hiqa's report reveals that expanding RSV vaccination to infants born during the RSV season or all babies during their first RSV season could lead to substantial reductions in hospitalisations. The study considered various immunisation products, including maternal vaccines and monoclonal antibodies. All approaches proved safe and effective, with the greatest benefit observed in infants.
This finding is particularly crucial given the high number of young children, especially infants, who require hospitalisation during RSV season. The report estimates that over 7,000 people are diagnosed with RSV annually in Ireland, with a significant portion of these cases involving young children.
Cost Implications
The cost of implementing these vaccination strategies varies. Providing the maternal vaccine to pregnant women during the RSV season could cost €15.6 million over five years. In contrast, a strategy offering monoclonal antibodies to all babies during their first RSV season would be more expensive, at €58.5 million. However, it's important to note that these costs come with a degree of uncertainty.
Older Adult Population
The assessment also examined RSV vaccination for older adults, aged 80 and above, who are at a higher risk of severe illness. While the vaccines are safe and effective, their one-off dose nature leads to waning effectiveness over time. The estimated cost of offering the vaccine to this age group is €70.6 million over five years, making it cost-ineffective at the current list price of €165 (excluding VAT).
Broader Healthcare Impact
Dr. Máirín Ryan, deputy chief executive of Hiqa, emphasises the substantial burden RSV places on vulnerable groups and healthcare systems. The virus results in numerous hospital discharges and ICU stays for young children, particularly those under one year old. Additionally, RSV surges can disrupt scheduled care and strain healthcare resources.
Personal Perspective
In my opinion, the Hiqa report underscores the importance of expanding RSV vaccination to infants. The potential reduction in hospitalisations and the positive impact on public health are compelling. However, the high costs associated with certain strategies raise important questions about resource allocation within the healthcare system. Balancing the benefits and costs will be crucial in making informed decisions.
Future Considerations
This assessment opens up discussions about the future of RSV prevention in Ireland. Exploring alternative vaccination strategies, such as adjusting the age groups or considering more frequent dosing for older adults, could be valuable. Additionally, the report highlights the need for ongoing research to refine cost estimates and ensure the most effective use of limited healthcare resources.
In conclusion, the Hiqa report provides valuable insights into RSV prevention and highlights the potential benefits of expanding vaccination to infants. While the costs are significant, the potential reduction in hospitalisations and the broader public health impact make it a worthwhile consideration. As we navigate the complexities of healthcare decision-making, this assessment serves as a crucial guide for policymakers and healthcare professionals.
